{"disease":{"id":"retinal-vein-occlusion","name":"retinal vein occlusion"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"dexamethasone","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"eylea","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Macular Edema Following Retinal Vein Occlusion (RVO)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06213896","title":"Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi","has_results":false},{"nct_id":"NCT06495203","title":"A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO","phase":"","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04505618","title":"Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06439576","title":"Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06757595","title":"Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT05222633","title":"Anti-VEGF in Real-world","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Wenbin Wei","has_results":false},{"nct_id":"NCT05850520","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":892,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT04740931","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":729,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00168298","title":"A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":668,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01496625","title":"National Eye Institute Biorepository for Retinal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00168324","title":"A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01571557","title":"A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)","phase":"","overall_status":"COMPLETED","enrollment_count":573,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04592419","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":568,"lead_sponsor_name":"Kodiak Sciences Inc","has_results":true},{"nct_id":"NCT04740905","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03810313","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":493,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02980874","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":460,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT03802630","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":450,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05675540","title":"Artificial Intelligence Diagnostic Aid","phase":"","overall_status":"UNKNOWN","enrollment_count":422,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT07514559","title":"Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":393,"lead_sponsor_name":"Hospital Hietzing","has_results":false},{"nct_id":"NCT02040220","title":"Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)","phase":"","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05520177","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03203447","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":325,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT01918371","title":"A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01427751","title":"Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03525132","title":"Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":290,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT01976338","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03108352","title":"Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT01976312","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03223714","title":"Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT04395859","title":"Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT04455399","title":"Time Efficiency Comparison of Two IntraVitreal Injection Techniques","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Peregrine Eye and Laser Institute","has_results":false},{"nct_id":"NCT04516278","title":"A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07002372","title":"Effect of Video Viewing on Intravitreal Injection Experience","phase":"NA","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03056079","title":"Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":168,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT03056092","title":"Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":168,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT02800642","title":"Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT07205887","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT07328776","title":"An Assistant Model for Anti-VEGF Therapy Decision","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03908307","title":"Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT01573572","title":"Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT02645747","title":"Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05832996","title":"Cool vs Room-temperature Artificial Tears","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"University of Iowa","has_results":true},{"nct_id":"NCT03790852","title":"Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":121,"lead_sponsor_name":"Kodiak Sciences Inc","has_results":false},{"nct_id":"NCT00101764","title":"Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}